Thomas D. Anderson

Biological researchers need to identify how new drugs and biologics works within cells. To do so, they test these products in cell lines: human cells propagated in lab culture. These cell lines are often genetically altered in order to study a specific protein but current processes take 4-6 months, the modifications are limited, and altered cells are often killed in order to study the protein of interest. ExpressCells has a superior technology that does not have these limitations. We use CRISPR plus our proprietary genetic vector system to create custom cells for research 4X faster. Our living cells can replicate diseases or have proteins glow in multiple colors. Learn more by following us on Twitter at https://twitter.com/expresscells

SwanBio is now part of Spur Therapeutics. Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more at spurtherapeutics.com.

An international association of CEOs that range from new CEOs to experienced board directors, every company size and ownership model: public, private and entrepreneurial, every industry. The CEO Trust is where CEOs come together. Trustees (members) share important values in common, which, because subscribed by all, create a warm, supportive environment. The mission for the CEO Trust is for us, as fellow CEO Trustees (members), to foster a collaborative environment of authentic leaders and generous spirits where CEOs can come together. Those interactions lead to unforgettable exchanges, breakthrough insights and new and strengthening relationships.

Philadelphia Alliance for Capital and Technologies (PACT) provides members with valuable connectivity to capital, talent and customers for growth acceleration and success. PACT also collaborates with fellow organizations to drive innovation and entrepreneurship in the Philadelphia region.

We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.

Biological researchers need to identify how new drugs and biologics works within cells. To do so, they test these products in cell lines: human cells propagated in lab culture. These cell lines are often genetically altered in order to study a specific protein but current processes take 4-6 months, the modifications are limited, and altered cells are often killed in order to study the protein of interest. ExpressCells has a superior technology that does not have these limitations. We use CRISPR plus our proprietary genetic vector system to create custom cells for research 4X faster. Our living cells can replicate diseases or have proteins glow in multiple colors. Learn more by following us on Twitter at https://twitter.com/expresscells

SwanBio is now part of Spur Therapeutics. Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more at spurtherapeutics.com.

Robin Hood Ventures is a group of angel investors, focused on early-stage, high-growth companies in the Greater Philadelphia region. We help entrepreneurs build great companies, providing capital, mentoring, expertise and connections to help companies reach their potential. Robin Hood generally invests $250k to $500k, and collaborates with angels, institutions and VCs in our network. We invest as a single entity in businesses we know and understand, in a way that gets deals done. Since 1999, we have invested in over 45 companies in industries including software, medical devices, biotech, internet and financial technology.